Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Why do medicines run out?
3 November 2026
Grace Hampson is joined by Ross Maclagan, Head of Supply and Distribution Policy at the ABPI, and Amanda Cole, Director at the Office of Health Economics,…
The economic and health impact of UK CEiRSI: the UK Centre of Excellence for In-Silico Regulatory Science and Innovation
21 October 2026
Investing in the UK Centre of Excellence for in-silico Regulatory Science & Innovation (CEiRSI) could accelerate the adoption of in-silico technologies in the UK. Doing so could improve patient access to innovation, reduce NHS costs and strengthen the UK’s position as a global leader in in- silico technology and life sciences.
Immunoglobulin sustainability in the United Kingdom
8 October 2026
Our report, commissioned and funded by argenx, looks at the challenges to Ig sustainability and assesses four potential policy responses.
When antibiotics stop working: the hidden crisis in plain sight
12 May 2026
Grace Hampson is joined by Lotte Steuten, Deputy CEO of the Office of Health Economics and David McKinney, Co-founder of ARMoR, to dig into the market failures surrounding the AMR crisis and…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical revenues might affect R&D incentives, but the Congressional Budget Office’s (CBO) revised simulation model of new drug development remains too simplified and insufficiently validated to guide real-world decisions.
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5 million hospital days and costs across the European Union (EU) and European Economic Area (EEA) economies €11.7 billion annually.
Europe’s pharmaceutical policy choices – And what the United States stands to learn
18 March 2026
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw from Europe’s experience with pharmaceutical pricing and innovation. As a participant, my key takeaways focused on understanding the trade-offs underpinning EU and UK drug pricing policy and the broader impact on innovation for both sides of the Atlantic.
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
Rare diseases may affect only a small number of people, but together they impact an estimated 300–400 million people worldwide — and only around 5% have an approved treatment. As global attention grows, including the WHO’s upcoming 10-year Global Action Plan, it is important to understand how regulation, HTA, and pricing policies across the UK, EU, and US influence the development of orphan medicines and access for patients.
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.